{
    "id": 17318,
    "fullName": "PTK2 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "PTK2 over exp indicates an over expression of the Ptk2 protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5747,
        "geneSymbol": "PTK2",
        "terms": [
            "PTK2",
            "FADK",
            "FAK",
            "FAK1",
            "FRNK",
            "p125FAK",
            "pp125FAK",
            "PPP1R71"
        ]
    },
    "variant": "over exp",
    "createDate": "01/28/2016",
    "updateDate": "01/28/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5939,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, patients with metastatic clear-cell renal cell carcinoma and PTK2 over did not show a progression-free survival benefit when treated with Saracatinib (AZD0530) and Recentin (cediranib) relative to Recentin (cediranib) alone, but did show overall survival benefit (Hazard Ratio 2.29 (1.09-4.82), P > 0.05) (PMID: 26802156).",
            "molecularProfile": {
                "id": 17604,
                "profileName": "PTK2 over exp"
            },
            "therapy": {
                "id": 3922,
                "therapyName": "Cediranib + Saracatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4467,
                "name": "clear cell renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5202,
                    "pubMedId": 26802156,
                    "title": "A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26802156"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12807,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CEP-37440 inhibited Ptk2 (Fak) phosphorylation, resulting in growth inhibition of inflammatory breast carcinoma cell lines with elevated Ptk2 (Fak) expression in culture and in cell line xenograft models (PMID: 27009091).",
            "molecularProfile": {
                "id": 17604,
                "profileName": "PTK2 over exp"
            },
            "therapy": {
                "id": 2147,
                "therapyName": "CEP-37440",
                "synonyms": null
            },
            "indication": {
                "id": 6263,
                "name": "inflammatory breast carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10721,
                    "pubMedId": 27009091,
                    "title": "The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27009091"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4272,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ovarian carcinoma cells over expressing Ptk2 were sensitive to VS-4718 (PMID: 24899686).",
            "molecularProfile": {
                "id": 17604,
                "profileName": "PTK2 over exp"
            },
            "therapy": {
                "id": 1933,
                "therapyName": "VS-4718",
                "synonyms": null
            },
            "indication": {
                "id": 4001,
                "name": "ovarian carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4361,
                    "pubMedId": 24899686,
                    "title": "FAK Inhibition disrupts a \u03b25 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24899686"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4271,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ovarian carcinoma cells over expressing Ptk2 were sensitive to PF-562271 in mouse models, resulting in decreased phosphorylation of Ptk2 and reduced tumor growth (PMID: 24899686).",
            "molecularProfile": {
                "id": 17604,
                "profileName": "PTK2 over exp"
            },
            "therapy": {
                "id": 2087,
                "therapyName": "PF-562271",
                "synonyms": null
            },
            "indication": {
                "id": 4001,
                "name": "ovarian carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4361,
                    "pubMedId": 24899686,
                    "title": "FAK Inhibition disrupts a \u03b25 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24899686"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 17604,
            "profileName": "PTK2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}